Literature DB >> 23363957

New insights into how HBV manipulates the innate immune response to establish acute and persistent infection.

Peter Revill1, Zhenghong Yuan.   

Abstract

The mechanisms by which HBV establishes and maintains chronic infection are poorly understood. Although adult acquired HBV is generally cleared by a robust immune response, most individuals infected at childbirth or in very early childhood develop lifelong chronic infection. In addition, acute infections are unresolved in approximately 5% of individuals infected in adulthood. The host cell mechanisms that ensure establishment and resolution of acute infection and persistent infection remain unclear. Currently, two schools of thought suggest that either HBV is a 'stealth' virus, which initially establishes infection by avoiding host innate immune responses, or that HBV facilitates initial infection and progression to persistence by actively manipulating the host innate immune response to its advantage. There is increasing evidence that activation of innate host cell signalling pathways plays a major role in limiting adult acquired HBV infection and that, in turn, HBV has evolved numerous strategies to counteract these defence mechanisms. In this review, we summarize current knowledge regarding innate immune responses to HBV infection and discuss how HBV regulates cell signalling pathways to its advantage, particularly in the setting of chronic HBV infection. In turn, we show how an intimate knowledge of innate immune responses is driving development of novel therapeutic agents to treat chronic HBV infection.

Entities:  

Mesh:

Year:  2013        PMID: 23363957     DOI: 10.3851/IMP2542

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  20 in total

Review 1.  Gut microbiota modulate the immune effect against hepatitis B virus infection.

Authors:  D Xu; Y Huang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-14       Impact factor: 3.267

2.  An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases.

Authors:  Jieliang Chen; Wen Zhang; Junyu Lin; Fan Wang; Min Wu; Cuncun Chen; Ye Zheng; Xiuhua Peng; Jianhua Li; Zhenghong Yuan
Journal:  Mol Ther       Date:  2013-09-12       Impact factor: 11.454

Review 3.  The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals.

Authors:  Ahmed Diab; Adrien Foca; Fabien Zoulim; David Durantel; Ourania Andrisani
Journal:  Antiviral Res       Date:  2017-11-26       Impact factor: 5.970

Review 4.  Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.

Authors:  Jieliang Chen; Zhenghong Yuan
Journal:  Virol Sin       Date:  2014-01-20       Impact factor: 4.327

Review 5.  Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.

Authors:  Yun Zhou; Ying Zhang; Jonathan P Moorman; Zhi Q Yao; Zhan S Jia
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

6.  Functionally aberrant dendritic cell subsets and expression of DC-SIGN differentiate acute from chronic HBV infection.

Authors:  Sukriti Sukriti; Nirupma Trehanpati; Manoj Kumar; Chandana Pande; Syed S Hissar; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-09-22       Impact factor: 6.047

7.  Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen.

Authors:  S Jegaskanda; S H Ahn; N Skinner; A J Thompson; T Ngyuen; J Holmes; R De Rose; M Navis; W R Winnall; M Kramski; G Bernardi; J Bayliss; D Colledge; V Sozzi; K Visvanathan; S A Locarnini; S J Kent; P A Revill
Journal:  J Virol       Date:  2014-05-28       Impact factor: 5.103

8.  Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen.

Authors:  Baocun Li; Yang Wang; Fang Shen; Min Wu; Yaming Li; Zhong Fang; Jianyu Ye; Li Wang; Lu Gao; Zhenghong Yuan; Jieliang Chen
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

9.  Phylogeography and evolutionary history of hepatitis B virus genotype F in Brazil.

Authors:  Francisco C A Mello; Oscar C Araujo; Barbara V Lago; Ana Rita C Motta-Castro; Marcia Terezinha B Moraes; Selma A Gomes; Gonzalo Bello; Natalia M Araujo
Journal:  Virol J       Date:  2013-07-16       Impact factor: 4.099

10.  Novel point and combo-mutations in the genome of hepatitis B virus-genotype D: characterization and impact on liver disease progression to hepatocellular carcinoma.

Authors:  Somenath Datta; Alip Ghosh; Debanjali Dasgupta; Amit Ghosh; Shrabasti Roychoudhury; Gaurav Roy; Soumyojit Das; Kausik Das; Subash Gupta; Keya Basu; Analabha Basu; Simanti Datta; Abhijit Chowdhury; Soma Banerjee
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.